

The lung as a route for systemic delivery of therapeutic

Respiratory Research

2, 198

DOI: 10.1186/rr58

Citation Report

#	ARTICLE	IF	CITATIONS
1	New polymeric carriers for controlled drug delivery following inhalation or injection. <i>Biomaterials</i> , 2002, 23, 4425-4433.	5.7	149
2	Pulmonary absorption of insulin mediated by tetradecyl-beta-maltoside and dimethyl-beta-cyclodextrin. <i>Pharmaceutical Research</i> , 2003, 20, 1551-1557.	1.7	45
3	Nebulization of biodegradable nanoparticles: impact of nebulizer technology and nanoparticle characteristics on aerosol features. <i>Journal of Controlled Release</i> , 2003, 86, 131-144.	4.8	151
4	Evaluation of nose-only aerosol inhalation chamber and comparison of experimental results with mathematical simulation of aerosol deposition in mouse lungs. <i>Journal of Pharmaceutical Sciences</i> , 2003, 92, 1066-1076.	1.6	53
5	Gene therapy progress and prospects: gene therapy of lysosomal storage disorders. <i>Gene Therapy</i> , 2003, 10, 1275-1281.	2.3	106
6	Recent Advances in Drug Delivery Via Pressured Metered-Dose Inhalers. , 2003, , 105-121.		4
7	Absorption enhancers in pulmonary protein delivery. <i>Journal of Controlled Release</i> , 2004, 94, 15-24.	4.8	149
8	Cyclodextrins as a potential carrier in drug nebulization. <i>Journal of Controlled Release</i> , 2004, 96, 403-410.	4.8	70
9	Poly(ether-anhydride) dry powder aerosols for sustained drug delivery in the lungs. <i>Journal of Controlled Release</i> , 2004, 96, 411-423.	4.8	72
10	Stabilized dynorphin derivatives for modulating antinociceptive activity in morphine tolerant rats: Effect of different routes of administration. <i>AAPS Journal</i> , 2004, 6, 68-73.	2.2	17
11	Pulmonary Delivery of Deslorelin: Large-Porous PLGA Particles and HP- β -CD Complexes. <i>Pharmaceutical Research</i> , 2004, 21, 1119-1126.	1.7	66
12	Waiting to inhale: Noninjectable insulin, are we there yet?. <i>Current Diabetes Reports</i> , 2004, 4, 335-341.	1.7	8
13	Optimized dose delivery of the peptide cyclosporine using hydrofluoroalkane-based metered dose inhalers. <i>Journal of Pharmaceutical Sciences</i> , 2004, 93, 1054-1061.	1.6	31
14	Pulmonary delivery of therapeutic peptides via dry powder inhalation: effects of micronisation and manufacturing. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2004, 58, 7-14.	2.0	67
15	Biochemie und Molekularbiologie 2003. <i>Nachrichten Aus Der Chemie</i> , 2004, 52, 292-305.	0.0	0
16	Carrageenans can regulate the pulmonary absorption of antiasthmatic drugs and their retention in the rat lung tissues without any membrane damage. <i>International Journal of Pharmaceutics</i> , 2005, 293, 63-72.	2.6	19
17	The effects of polyvinyl alcohol on the in vitro stability and delivery of spray-dried protein particles from surfactant-free HFA 134a-based pressurised metered dose inhalers. <i>International Journal of Pharmaceutics</i> , 2005, 304, 29-39.	2.6	44
18	Carrier-based strategies for targeting protein and peptide drugs to the lungs. <i>AAPS Journal</i> , 2005, 7, E20-E41.	2.2	130

#	ARTICLE	IF	CITATIONS
19	Influence of flow rate on the disposition of levofloxacin and netilmicin in the isolated rat lung. <i>European Journal of Pharmaceutical Sciences</i> , 2005, 24, 325-332.	1.9	8
20	The pharmacokinetics of pulmonary insulin in the in vitro isolated perfused rat lung: Implications of metabolism and regional deposition. <i>European Journal of Pharmaceutical Sciences</i> , 2005, 25, 369-378.	1.9	36
21	Effect of device inhalational resistance on the three-dimensional configuration of the upper airway. <i>Journal of Pharmaceutical Sciences</i> , 2005, 94, 1418-1426.	1.6	11
22	Chitosan Oligomers as Potential and Safe Absorption Enhancers for Improving the Pulmonary Absorption of Interferon- β in Rats. <i>Journal of Pharmaceutical Sciences</i> , 2005, 94, 2432-2440.	1.6	47
23	Transdermal Delivery of Human Growth Hormone Through RF-Microchannels. <i>Pharmaceutical Research</i> , 2005, 22, 550-555.	1.7	118
24	Antibody Response to Inhaled Insulin in Patients with Type 1 or Type 2 Diabetes. An Analysis of Initial Phase II and III Inhaled Insulin (Exubera) Trials and a Two-Year Extension Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 3287-3294.	1.8	139
25	Full deacylation of polyethylenimine dramatically boosts its gene delivery efficiency and specificity to mouse lung. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 5679-5684.	3.3	344
26	Inhaled insulin for diabetes mellitus. <i>American Journal of Health-System Pharmacy</i> , 2005, 62, 1359-1364.	0.5	64
27	The Lung, an Organ for Absorption?. <i>Respiration</i> , 2005, 72, 552-558.	1.2	9
28	Human respiratory epithelial cell culture for drug delivery applications. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2005, 60, 193-205.	2.0	266
29	Nebulization of Liposomal rh-Cu/Zn-SOD with a Novel Vibrating Membrane Nebulizer. <i>Journal of Liposome Research</i> , 2006, 16, 113-125.	1.5	34
30	Control of Physical Forms of Drug Particles for Pulmonary Delivery by Spray Drying and Supercritical Fluid Processing. <i>KONA Powder and Particle Journal</i> , 2006, 24, 27-40.	0.9	17
31	The present state and future of dry powder inhalation system. <i>Drug Delivery System</i> , 2006, 21, 417-425.	0.0	4
32	Pharmacokinetics and Anti-asthmatic Potential of Non-parenterally Administered Recombinant Human Interleukin-1 Receptor Antagonist in Animal Models. <i>Journal of Pharmacological Sciences</i> , 2006, 102, 321-330.	1.1	18
33	Development of liposomal capreomycin sulfate formulations: Effects of formulation variables on peptide encapsulation. <i>International Journal of Pharmaceutics</i> , 2006, 311, 172-181.	2.6	52
34	Prospects of formulating proteins/peptides as aerosols for pulmonary drug delivery. <i>International Journal of Pharmaceutics</i> , 2006, 314, 1-8.	2.6	113
35	In vitro evaluation of the effect of cyclodextrin complexation on pulmonary deposition of a peptide, cyclosporin A. <i>International Journal of Pharmaceutics</i> , 2006, 318, 41-48.	2.6	21
36	Clinical perspectives on pulmonary systemic and macromolecular delivery. <i>Advanced Drug Delivery Reviews</i> , 2006, 58, 996-1008.	6.6	152

#	ARTICLE	IF	CITATIONS
37	Pharmacology of bile acids and their derivatives: Absorption promoters and therapeutic agents. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2006, 31, 237-251.	0.6	67
39	Cyclodextrins in the production of large porous particles: Development of dry powders for the sustained release of insulin to the lungs. <i>European Journal of Pharmaceutical Sciences</i> , 2006, 28, 423-432.	1.9	118
40	Delivering Needle-Free Insulin Using AERx® iDMS (Insulin Diabetes Management System) Technology. <i>Diabetes Technology and Therapeutics</i> , 2007, 9, S-57-S-64.	2.4	17
42	Inhalation, Deposition, and Fate of Insulin and Other Therapeutic Proteins. <i>Diabetes Technology and Therapeutics</i> , 2007, 9, S-4-S-15.	2.4	59
43	Inhaled Insulin for Diabetes Mellitus. <i>New England Journal of Medicine</i> , 2007, 356, 497-502.	13.9	54
44	Novel approaches in microparticulate PLGA delivery systems encapsulating proteins. <i>Journal of Materials Chemistry</i> , 2007, 17, 4002.	6.7	53
45	IL-1 Receptor Antagonist as an Aerosol in Inflammation. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2007, 20, 445-459.	1.2	5
46	Long acting porous microparticle for pulmonary protein delivery. <i>International Journal of Pharmaceutics</i> , 2007, 333, 5-9.	2.6	89
47	Absorption enhancement of poorly absorbed hydrophilic compounds from various mucosal sites by combination of mucolytic agent and non-ionic surfactant. <i>International Journal of Pharmaceutics</i> , 2007, 338, 87-93.	2.6	16
48	Characterization of human insulin microcrystals and their absorption enhancement by protease inhibitors in rat lungs. <i>International Journal of Pharmaceutics</i> , 2007, 339, 205-212.	2.6	23
49	Artificial pulmonary surfactant as a carrier for intratracheally instilled insulin. <i>Acta Pharmacologica Sinica</i> , 2007, 28, 744-750.	2.8	3
50	Solid lipid nanoparticles as a drug delivery system for peptides and proteins. <i>Advanced Drug Delivery Reviews</i> , 2007, 59, 478-490.	6.6	712
51	Current challenges in non-invasive insulin delivery systems: A comparative review. <i>Advanced Drug Delivery Reviews</i> , 2007, 59, 1521-1546.	6.6	367
52	In vivo animal models for drug delivery across the lung mucosal barrier. <i>Advanced Drug Delivery Reviews</i> , 2007, 59, 1133-1151.	6.6	132
53	Complexation of a Poly-L-Arginine with Low Molecular Weight Heparin Enhances Pulmonary Absorption of the Drug. <i>Pharmaceutical Research</i> , 2008, 25, 936-948.	1.7	21
54	Core-shell Particles for the Dispersion of Small Polar Drugs and Biomolecules in Hydrofluoroalkane Propellants. <i>Pharmaceutical Research</i> , 2008, 25, 289-301.	1.7	29
55	Aerodynamical, Immunological and Pharmacological Properties of the Anticancer Antibody Cetuximab Following Nebulization. <i>Pharmaceutical Research</i> , 2008, 25, 1318-1326.	1.7	51
56	Prolonged antidiabetic effect of zinc-crystallized insulin loaded glycol chitosan nanoparticles in type 1 diabetic rats. <i>Archives of Pharmacal Research</i> , 2008, 31, 918-923.	2.7	11

#	ARTICLE	IF	CITATIONS
57	Effect of dimethyl- α -cyclodextrin concentrations on the pulmonary delivery of recombinant human growth hormone dry powder in rats. <i>Journal of Pharmaceutical Sciences</i> , 2008, 97, 5176-5185.	1.6	33
58	Supercritical fluid-micronized ipratropium bromide for pulmonary drug delivery. <i>Powder Technology</i> , 2008, 182, 25-32.	2.1	37
59	Effect of albumin on physical characteristics of drug particles produced by supercritical fluid technology. <i>Powder Technology</i> , 2008, 182, 354-363.	2.1	18
60	Preparation and properties of inhalable nanocomposite particles: Effects of the temperature at a spray-dryer inlet upon the properties of particles. <i>Colloids and Surfaces B: Biointerfaces</i> , 2008, 61, 138-144.	2.5	43
61	Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration. <i>International Journal of Pharmaceutics</i> , 2008, 356, 231-238.	2.6	75
62	Inhalable liposomal formulation for vasoactive intestinal peptide. <i>International Journal of Pharmaceutics</i> , 2008, 357, 286-294.	2.6	67
63	Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: Optimization by PEG size selection. <i>Journal of Controlled Release</i> , 2008, 125, 68-75.	4.8	71
64	Inhalable large porous microspheres of low molecular weight heparin: In vitro and in vivo evaluation. <i>Journal of Controlled Release</i> , 2008, 128, 224-232.	4.8	125
65	Dry powder inhalation systems for pulmonary delivery of therapeutic peptides and proteins. <i>Expert Opinion on Therapeutic Patents</i> , 2008, 18, 429-442.	2.4	27
66	Pulmonary delivery of scutellarin solution and mucoadhesive particles in rats. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2008, 70, 845-852.	2.0	34
67	Spray-freeze-dried dry powder inhalation of insulin-loaded liposomes for enhanced pulmonary delivery. <i>Journal of Drug Targeting</i> , 2008, 16, 639-648.	2.1	96
68	Pulmonary delivery of ISCOMATRIX influenza vaccine induces both systemic and mucosal immunity with antigen dose sparing. <i>Mucosal Immunology</i> , 2008, 1, 489-496.	2.7	64
69	Rapid generation of protein aerosols and nanoparticles via surface acoustic wave atomization. <i>Nanotechnology</i> , 2008, 19, 455103.	1.3	103
70	Increased Biological Half-Life of Aerosolized Liposomal Recombinant Human Cu/Zn Superoxide Dismutase in Pigs. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2008, 21, 281-290.	0.7	23
73	Particle size design of PLGA microspheres for potential pulmonary drug delivery using response surface methodology. <i>Journal of Microencapsulation</i> , 2009, 26, 1-8.	1.2	45
74	Various Non-Injectable Delivery Systems for the Treatment of Diabetes Mellitus. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2009, 9, 1-13.	0.6	38
75	The arrival of genetic engineering. <i>IEEE Engineering in Medicine and Biology Magazine</i> , 2009, 28, 40-54.	1.1	0
76	The effect of process parameters on the size and morphology of poly(D,L-lactide-co-glycolide) micro/nanoparticles prepared by an oil in oil emulsion/solvent evaporation technique. <i>Journal of Applied Polymer Science</i> , 2010, 116, 528-534.	1.3	6

#	ARTICLE	IF	CITATIONS
77	Templated Open Flocs of Nanorods for Enhanced Pulmonary Delivery with Pressurized Metered Dose Inhalers. <i>Pharmaceutical Research</i> , 2009, 26, 101-117.	1.7	41
78	Influence of Stabilizers on the Physicochemical Characteristics of Inhaled Insulin Powders Produced by Supercritical Antisolvent Process. <i>Pharmaceutical Research</i> , 2009, 26, 61-71.	1.7	20
79	Forces between insulin microspheres and polymers surfaces for a dry powder inhaler. <i>International Journal of Pharmaceutics</i> , 2009, 372, 147-153.	2.6	6
80	Novel dry powder inhaler formulation of glucagon with addition of citric acid for enhanced pulmonary delivery. <i>International Journal of Pharmaceutics</i> , 2009, 382, 144-150.	2.6	13
81	Preparation of microsized spherical aggregates of ultrafine ciprofloxacin particles for dry powder inhalation (DPI). <i>Powder Technology</i> , 2009, 194, 81-86.	2.1	23
82	Impact of absorption and transport on intelligent therapeutics and nanoscale delivery of protein therapeutic agents. <i>Chemical Engineering Science</i> , 2009, 64, 4553-4565.	1.9	32
83	Characterization and in vitro evaluation of the formoterol/cyclodextrin complex for pulmonary administration by nebulization. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2009, 72, 214-218.	2.0	20
84	Intrapulmonary potential of polyethylene glycol-modified glucagon-like peptide-1s as a type 2 anti-diabetic agent. <i>Regulatory Peptides</i> , 2009, 152, 101-107.	1.9	36
85	Pulmonary delivery of recombinant acid sphingomyelinase improves clearance of lysosomal sphingomyelin from the lungs of a murine model of Niemann-Pick disease. <i>Molecular Genetics and Metabolism</i> , 2009, 97, 35-42.	0.5	10
86	Low cytotoxicity of solid lipid nanoparticles in <i>in vitro</i> and <i>ex vivo</i> lung models. <i>Inhalation Toxicology</i> , 2009, 21, 104-109.	0.8	84
87	New treatments for chronic obstructive pulmonary disease and viable formulation/device options for inhalation therapy. <i>Expert Opinion on Drug Delivery</i> , 2009, 6, 793-811.	2.4	23
88	Preparation of Macromolecule-Containing Dry Powders for Pulmonary Delivery. <i>Methods in Molecular Biology</i> , 2009, 480, 165-174.	0.4	9
89	Novel methods of targeted drug delivery: the potential of multifunctional nanoparticles. <i>Expert Review of Clinical Pharmacology</i> , 2009, 2, 265-282.	1.3	27
90	Nanomedicine in pulmonary delivery. <i>International Journal of Nanomedicine</i> , 2009, 4, 299.	3.3	378
91	Mechanism of Insulin Uptake in Rat Alveolar Type II and Type I-Like Epithelial Cells. <i>Biological and Pharmaceutical Bulletin</i> , 2009, 32, 1765-1769.	0.6	17
92	Novel devices for individualized controlled inhalation can optimize aerosol therapy in efficacy, patient care and power of clinical trials. <i>European Journal of Medical Research</i> , 2009, 14, 71.	0.9	53
93	Effect of Particle Formulation on Dry Powder Inhalation Efficiency. <i>Current Pharmaceutical Design</i> , 2010, 16, 2377-2387.	0.9	31
94	Problems and Examples of Biomolecule Inhalation for Systemic Treatment. , 2010, , 67-76.		0

#	ARTICLE	IF	CITATIONS
95	Nanoparticles of glycol chitosan and its thiolated derivative significantly improved the pulmonary delivery of calcitonin. International Journal of Pharmaceutics, 2010, 397, 92-95.	2.6	98
96	Protein microspheres for pulmonary drug delivery. Frontiers of Chemical Engineering in China, 2010, 4, 82-86.	0.6	2
97	Inhaled insulin—Intrapulmonary, intranasal, and other routes of administration: Mechanisms of action. Nutrition, 2010, 26, 33-39.	1.1	51
98	Intranasal insulin: From nose to brain. Nutrition, 2010, 26, 624-633.	1.1	39
99	Engineering gas-foamed large porous particles for efficient local delivery of macromolecules to the lung. European Journal of Pharmaceutical Sciences, 2010, 41, 60-70.	1.9	55
100	In Vitro Reporter Gene Transfection via Plasmid DNA Delivered by Metered Dose Inhaler. Journal of Pharmaceutical Sciences, 2010, 99, 3089-3099.	1.6	15
101	Technological Requirements for Inhalation of Biomolecule Aerosols. , 2010, , 60-66.		2
102	Delivering Horseradish Peroxidase as a Respirable Powder to the Isolated, Perfused, and Ventilated Lung of the Rat: The Pulmonary Disposition of an Inhaled Model Biopharmaceutical. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2010, 23, 273-284.	0.7	12
103	Inhalable Lactose-Based Dry Powder Formulations of Low Molecular Weight Heparin. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2010, 23, 97-104.	0.7	25
104	Single-use disposable dry powder inhalers for pulmonary drug delivery. Expert Opinion on Drug Delivery, 2010, 7, 1359-1372.	2.4	37
105	Diabetes Treatment by Inhalation of Insulin — Shine and Decline of a Novel Type of Therapy. , 2010, , 77-83.		1
106	Formulation and in vitro evaluation of highly dispersive insulin dry powder formulations for lung administration. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 76, 454-463.	2.0	27
107	Advances in the pulmonary delivery of poorly water-soluble drugs: influence of solubilization on pharmacokinetic properties. Drug Development and Industrial Pharmacy, 2010, 36, 1-30.	0.9	54
109	Lung epithelial binding peptide-linked high mobility group box-1 A box for lung epithelial cell-specific delivery of DNA. Journal of Drug Targeting, 2011, 19, 589-596.	2.1	6
110	Nanocarriers for pulmonary administration of peptides and therapeutic proteins. Nanomedicine, 2011, 6, 123-141.	1.7	62
111	<i>In vitro</i> and <i>in vivo</i> testing methods for respiratory drug delivery. Expert Opinion on Drug Delivery, 2011, 8, 57-69.	2.4	38
112	Surfactants: their critical role in enhancing drug delivery to the lungs. Therapeutic Delivery, 2011, 2, 623-641.	1.2	28
113	The Delivery of Drugs — Peptides and Proteins. , 2011, , 587-604.		7

#	ARTICLE	IF	CITATIONS
114	Human growth hormone: New delivery systems, alternative routes of administration, and their pharmacological relevance. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2011, 78, 278-288.	2.0	32
115	Pulmonary Drug Delivery: Novel Pharmaceutical Technologies Breathe New Life into the Lungs. <i>PDA Journal of Pharmaceutical Science and Technology</i> , 2011, 65, 513-534.	0.3	20
116	Potentials and Limitations of Bile Acids and Probiotics in Diabetes Mellitus. , 2011, , .		5
117	Transport of Proteins and Peptides and its Regulation in Alveolar Epithelial Cells. <i>Membrane</i> , 2011, 36, 145-153.	0.0	4
118	Protein and Peptide Delivery through Respiratory Pathway. , 2011, , 429-479.		8
119	Antioxidant encapsulated porous poly(lactide-co-glycolide) microparticles for developing long acting inhalation system. <i>Colloids and Surfaces B: Biointerfaces</i> , 2011, 88, 419-424.	2.5	31
120	Mechanism underlying insulin uptake in alveolar epithelial cell line RLE-6TN. <i>European Journal of Pharmacology</i> , 2011, 672, 62-69.	1.7	17
121	Inhalable Sustained-Release Formulation of Glucagon: In Vitro Amyloidogenic and Inhalation Properties, and In Vivo Absorption and Bioactivity. <i>Pharmaceutical Research</i> , 2011, 28, 1157-1166.	1.7	17
122	Albumin-Coated Porous Hollow Poly(Lactic-co-Glycolic Acid) Microparticles Bound with Palmitoyl-Acylated Exendin-4 as a Long-Acting Inhalation Delivery System for the Treatment of Diabetes. <i>Pharmaceutical Research</i> , 2011, 28, 2008-2019.	1.7	45
123	The MTT assay as tool to evaluate and compare excipient toxicity in vitro on respiratory epithelial cells. <i>International Journal of Pharmaceutics</i> , 2011, 411, 98-105.	2.6	82
124	Lung vascular targeting through inhalation delivery: Insight from filamentous viruses and other shapes. <i>IUBMB Life</i> , 2011, 63, 607-612.	1.5	27
125	Microspheres loaded with polysaccharide nanoparticles for pulmonary delivery: Preparation, structure and surface analysis. <i>Carbohydrate Polymers</i> , 2011, 86, 25-34.	5.1	51
126	New insights into respirable protein powder preparation using a nano spray dryer. <i>International Journal of Pharmaceutics</i> , 2011, 408, 248-256.	2.6	110
127	Pulmonary Drug Delivery System: A Novel Approach for Drug Delivery. <i>Current Drug Therapy</i> , 2011, 6, 137-151.	0.2	14
128	Aerosolized Gemcitabine in Patients with Carcinoma of the Lung: Feasibility and Safety Study. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2011, 24, 261-270.	0.7	60
129	Evaluating the Controlled Release Properties of Inhaled Nanoparticles Using Isolated, Perfused, and Ventilated Lung Models. <i>Journal of Nanomaterials</i> , 2011, 2011, 1-16.	1.5	26
130	Pulmonary Delivery of Interleukin-7 Provides Efficient and Safe Delivery to the Aging Immune System. <i>Rejuvenation Research</i> , 2012, 15, 414-422.	0.9	4
131	Enhancement Effect of Poly(amino acid)s on Insulin Uptake in Alveolar Epithelial Cells. <i>Drug Metabolism and Pharmacokinetics</i> , 2012, 27, 570-578.	1.1	5

#	ARTICLE	IF	CITATIONS
132	Spray drying from organic solvents to prepare nanoporous/nanoparticulate microparticles of protein: excipient composites designed for oral inhalation. <i>Journal of Pharmacy and Pharmacology</i> , 2012, 64, 1275-1290.	1.2	20
133	Pulmonary delivery of elcatonin using surface-modified liposomes to improve systemic absorption: Polyvinyl alcohol with a hydrophobic anchor and chitosan oligosaccharide as effective surface modifiers. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2012, 80, 340-346.	2.0	72
134	Influence of surface charge and inner composition of nanoparticles on intracellular delivery of proteins in airway epithelial cells. <i>Biomaterials</i> , 2012, 33, 9117-9126.	5.7	30
135	Has nanotechnology led to improved therapeutic outcomes?. <i>Drug Development and Industrial Pharmacy</i> , 2012, 38, 158-170.	0.9	34
136	Solid Lipid Nanoparticles (SLN): Method, Characterization and Applications. <i>International Current Pharmaceutical Journal</i> , 2012, 1, 384-393.	0.2	127
137	Pulmonary delivery of therapeutic siRNA. <i>Advanced Drug Delivery Reviews</i> , 2012, 64, 1-15.	6.6	177
138	Novel preparation techniques for alginate-polyoxamer microparticles controlling protein release on mucosal surfaces. <i>European Journal of Pharmaceutical Sciences</i> , 2012, 45, 358-366.	1.9	48
139	Mechanisms of absorption and elimination of drugs administered by inhalation. <i>Therapeutic Delivery</i> , 2013, 4, 1027-1045.	1.2	45
140	Emerging applications of nanoparticles for lung cancer diagnosis and therapy. <i>International Nano Letters</i> , 2013, 3, 1.	2.3	76
141	A design of experiments to optimize a new manufacturing process for high activity protein-containing submicron particles. <i>Drug Development and Industrial Pharmacy</i> , 2013, 39, 1793-1801.	0.9	16
142	Airway delivery of peptides and proteins using nanoparticles. <i>Biomaterials</i> , 2013, 34, 516-525.	5.7	59
143	Inhaled proteins: Challenges and perspectives. <i>International Journal of Pharmaceutics</i> , 2013, 447, 251-280.	2.6	128
144	Porous microsphere and its applications. <i>International Journal of Nanomedicine</i> , 2013, 8, 1111.	3.3	107
146	Nanoporous microspheres: from controllable synthesis to healthcare applications. <i>Journal of Materials Chemistry B</i> , 2013, 1, 2222.	2.9	82
147	Basics and recent advances in peptide and protein drug delivery. <i>Therapeutic Delivery</i> , 2013, 4, 1443-1467.	1.2	542
148	Insulin and the Lung: Connecting Asthma and Metabolic Syndrome. <i>Journal of Allergy</i> , 2013, 2013, 1-8.	0.7	62
149	RNAi Therapeutic Platforms for Lung Diseases. <i>Pharmaceutics</i> , 2013, 6, 223-250.	1.7	78
151	Surface Modification of Liposomes Using Polymer-Wheat Germ Agglutinin Conjugates to Improve the Absorption of Peptide Drugs by Pulmonary Administration. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 1281-1289.	1.6	35

#	ARTICLE	IF	CITATIONS
152	A novel platform to enable inhaled naked RNAi medicine for lung cancer. <i>Scientific Reports</i> , 2013, 3, 3325.	1.6	44
153	Long-acting preparations of exenatide. <i>Drug Design, Development and Therapy</i> , 2013, 7, 963.	2.0	28
154	Biologics: the role of delivery systems in improved therapy. <i>Biologics: Targets and Therapy</i> , 2014, 8, 107.	3.0	63
155	Influence of potential inhalation carriers on stability of thymopentin in rat bronchoalveolar lavage fluid. <i>Drug Delivery</i> , 2014, 21, 495-500.	2.5	2
156	Needle-free injection of insulin powder: delivery efficiency and skin irritation assessment. <i>Journal of Zhejiang University: Science B</i> , 2014, 15, 888-899.	1.3	5
157	Routes of administration of insulin. , 2014, , 59-112.		3
158	Bioavailability of Therapeutic Proteins by Inhalationâ€™Worker Safety Aspects. <i>Annals of Occupational Hygiene</i> , 2014, 58, 899-911.	1.9	12
159	Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) for pulmonary application: A review of the state of the art. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2014, 86, 7-22.	2.0	427
160	A microdevice for parallelized pulmonary permeability studies. <i>Biomedical Microdevices</i> , 2014, 16, 277-285.	1.4	10
161	An overview of clinical and commercial impact of drug delivery systems. <i>Journal of Controlled Release</i> , 2014, 190, 15-28.	4.8	379
162	Colloidal carriers for noninvasive delivery of insulin. , 2014, , 411-442.		6
163	Controlled release of therapeutic antibody formats. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2014, 88, 291-309.	2.0	40
164	Agile delivery of protein therapeutics to CNS. <i>Journal of Controlled Release</i> , 2014, 190, 637-663.	4.8	88
165	Enhanced delivery of human growth hormone across cell membrane by Tat-PTD. <i>Endocrine</i> , 2014, 46, 138-147.	1.1	4
166	Generation, inhalation delivery and anti-hypertensive effect of nisoldipine nanoaerosol. <i>Journal of Aerosol Science</i> , 2014, 78, 41-54.	1.8	19
167	Polymeric nanoparticle system to target activated microglia/macrophages in spinal cord injury. <i>Journal of Controlled Release</i> , 2014, 174, 15-26.	4.8	100
168	Prediction of protein degradation during vibrating mesh nebulization via a high throughput screening method. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2014, 87, 386-394.	2.0	20
170	Developing accurate models of the human airways. <i>Journal of Pharmacy and Pharmacology</i> , 2015, 67, 464-472.	1.2	8

#	ARTICLE	IF	CITATIONS
172	Depot-Based Delivery Systems for Pro-Angiogenic Peptides: A Review. <i>Frontiers in Bioengineering and Biotechnology</i> , 2015, 3, 102.	2.0	48
173	Spray-Drying of Biopharmaceuticals. , 2015, , 273-297.		10
174	Novel potential for optimization of antitubercular therapy: Pulmonary delivery of rifampicin lipospheres. <i>Asian Journal of Pharmaceutical Sciences</i> , 2015, 10, 549-562.	4.3	17
175	Nebulization as a delivery method for mAbs in respiratory diseases. <i>Expert Opinion on Drug Delivery</i> , 2015, 12, 1027-1039.	2.4	105
176	Physicochemical and Formulation Developability Assessment for Therapeutic Peptide Deliveryâ€™A Primer. <i>AAPS Journal</i> , 2015, 17, 144-155.	2.2	66
177	Investigating the pharmacokinetics and biological distribution of silverâ€™loaded polyphosphoesterâ€™based nanoparticles using ¹¹¹ Ag as a radiotracer. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2015, 58, 234-241.	0.5	21
178	Drug delivery of Insulin-like growth factor I. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2015, 97, 329-337.	2.0	5
179	Receptor-mediated endocytosis of macromolecules and strategy to enhance their transport in alveolar epithelial cells. <i>Expert Opinion on Drug Delivery</i> , 2015, 12, 813-825.	2.4	27
180	Bio-inspired materials in drug delivery: Exploring the role of pulmonary surfactant in siRNA inhalation therapy. <i>Journal of Controlled Release</i> , 2015, 220, 642-650.	4.8	44
181	Protein stability in pulmonary drug delivery via nebulization. <i>Advanced Drug Delivery Reviews</i> , 2015, 93, 79-94.	6.6	81
182	Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins. <i>Journal of Immunology Research</i> , 2016, 2016, 1-9.	0.9	49
184	Systems Pharmacology Approach for Prediction of Pulmonary and Systemic Pharmacokinetics and Receptor Occupancy of Inhaled Drugs. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2016, 5, 201-210.	1.3	53
185	Aerosol Delivery of siRNA to the Lungs. Part 1: Rationale for Gene Delivery Systems. <i>KONA Powder and Particle Journal</i> , 2016, 33, 63-85.	0.9	38
186	Inhalation devices: from basic science to practical use, innovative vs generic products. <i>Expert Opinion on Drug Delivery</i> , 2016, 13, 1559-1571.	2.4	34
187	Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and development. <i>MABs</i> , 2016, 8, 229-245.	2.6	127
188	Functional and cytometric examination of different human lung epithelial cell types as drug transport barriers. <i>Archives of Pharmacal Research</i> , 2016, 39, 359-369.	2.7	11
189	Systemic delivery of parathyroid hormone (1â€™34) using spray freeze-dried inhalable particles. <i>Pharmaceutical Development and Technology</i> , 2017, 22, 733-739.	1.1	22
190	Emerging delivery platforms for mucosal administration of biopharmaceuticals: a critical update on nasal, pulmonary and oral routes. <i>Expert Opinion on Drug Delivery</i> , 2017, 14, 23-36.	2.4	69

#	ARTICLE	IF	CITATIONS
191	Nanobodies® – Nanobody is a registered trademark of Ablynx NV. as inhaled biotherapeutics for lung diseases. , 2017, 169, 47-56.		135
192	Arachidonic acid with taurine enhances pulmonary absorption of macromolecules without any serious histopathological damages. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 114, 22-28.	2.0	5
193	Challenges and Future Prospects for the Delivery of Biologics: Oral Mucosal, Pulmonary, and Transdermal Routes. AAPS Journal, 2017, 19, 652-668.	2.2	109
194	Optimization of Acetalated Dextran-Based Nanocomposite Microparticles for Deep Lung Delivery of Therapeutics via Spray-Drying. Journal of Pharmaceutical Sciences, 2017, 106, 3539-3547.	1.6	18
195	Suppression of Tobacco Carcinogen-Induced Lung Tumorigenesis by Aerosol-Delivered Glycerol Propoxylate Triacrylate-Spermine Copolymer/Short Hairpin Rab25 RNA Complexes in Female A/J Mice. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2017, 30, 81-90.	0.7	6
196	Bioresorbable polymer microparticles in the medical and pharmaceutical fields. , 2017, , 229-264.		5
197	FORMULATIONS AND TECHNOLOGIES IN GROWTH HORMONE DELIVERY. International Journal of Pharmacy and Pharmaceutical Sciences, 2017, 9, 1.	0.3	2
198	Development of Adjuvanted Solid Fat Nanoemulsions for Pulmonary Hepatitis B Vaccination. Journal of Pharmaceutical Sciences, 2018, 107, 1701-1712.	1.6	6
199	Foaming Processes. , 2018, , 131-188.		4
200	Pharmacokinetics and Pharmacodynamics of Nebulized and Intratracheal Milrinone in a Swine Model of Hypercapnia Pulmonary Hypertension. Journal of Cardiothoracic and Vascular Anesthesia, 2018, 32, 2130-2138.	0.6	6
201	Calcium Phosphate Particles as Pulmonary Delivery System for Interferon- β in Mice. AAPS PharmSciTech, 2018, 19, 395-412.	1.5	14
202	GABAB receptor ligand-directed trimethyl chitosan/tripolyphosphate nanoparticles and their pMDI formulation for survivin siRNA pulmonary delivery. Carbohydrate Polymers, 2018, 179, 135-144.	5.1	47
203	A Comprehensive Map of FDA-Approved Pharmaceutical Products. Pharmaceutics, 2018, 10, 263.	2.0	207
204	Formulation techniques for high dose dry powders. International Journal of Pharmaceutics, 2018, 547, 489-498.	2.6	46
205	Functionalized Polymeric Nanostructures for Mucosal Drug Delivery. , 2018, , 449-487.		2
206	Porous microspheres: Synthesis, characterisation and applications in pharmaceutical & medical fields. International Journal of Pharmaceutics, 2018, 548, 34-48.	2.6	89
207	Microspherical Particles of Solid Dispersion of Polyvinylpyrrolidone K29-32 for Inhalation Administration. BioMed Research International, 2018, 2018, 1-12.	0.9	11
208	Pharmacokinetics and pharmacodynamics of high doses of inhaled dry powder drugs. International Journal of Pharmaceutics, 2018, 549, 306-316.	2.6	23

#	ARTICLE	IF	CITATIONS
209	In silico approaches for predicting the half-life of natural and modified peptides in blood. PLoS ONE, 2018, 13, e0196829.	1.1	67
210	Application of disaccharides alone and in combination, for the improvement of stability and particle properties of spray-freeze dried IgG. Pharmaceutical Development and Technology, 2019, 24, 439-447.	1.1	6
211	Recent advances in aerosol gene delivery systems using non-viral vectors for lung cancer therapy. Expert Opinion on Drug Delivery, 2019, 16, 757-772.	2.4	24
212	Thermosensitive polysaccharide particles for pulmonary drug delivery. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2019, 580, 123720.	2.3	6
213	Nanocarriers in effective pulmonary delivery of siRNA: current approaches and challenges. Therapeutic Delivery, 2019, 10, 311-332.	1.2	18
214	Targeted PEG-poly(glutamic acid) complexes for inhalation protein delivery to the lung. Journal of Controlled Release, 2019, 316, 250-262.	4.8	23
215	Caproyl-Modified G2 PAMAM Dendrimer (G2-AC) Nanocomplexes Increases the Pulmonary Absorption of Insulin. AAPS PharmSciTech, 2019, 20, 298.	1.5	11
216	Recent Advancements in Non-Invasive Formulations for Protein Drug Delivery. Computational and Structural Biotechnology Journal, 2019, 17, 1290-1308.	1.9	114
217	Hydrogel microspheres evading alveolar macrophages for sustained pulmonary protein delivery. International Journal of Pharmaceutics, 2019, 566, 652-661.	2.6	24
218	Vibrating Mesh Nebulisation of Pro-Antimicrobial Peptides for Use in Cystic Fibrosis. Pharmaceutics, 2019, 11, 239.	2.0	16
219	Kinetic stability of amorphous solid dispersions with high content of the drug: A fast scanning calorimetry investigation. International Journal of Pharmaceutics, 2019, 562, 113-123.	2.6	24
220	Strategies to Enhance Drug Absorption via Nasal and Pulmonary Routes. Pharmaceutics, 2019, 11, 113.	2.0	165
221	Regenerative therapy based on miRNA-302 mimics for enhancing host recovery from pneumonia caused by <i>Streptococcus pneumoniae</i> . Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 8493-8498.	3.3	21
222	Recent Developments in mRNA-Based Protein Supplementation Therapy to Target Lung Diseases. Molecular Therapy, 2019, 27, 803-823.	3.7	60
223	Solid Lipid Nanoparticle-Based Drug Delivery for Lung Cancer. , 2019, , 95-121.		7
224	Comparison of asthma phenotypes in OVA-induced mice challenged via inhaled and intranasal routes. BMC Pulmonary Medicine, 2019, 19, 241.	0.8	60
225	Model-Based Drug Development in Pulmonary Delivery: Pharmacokinetic Analysis of Novel Drug Candidates for Treatment of Pseudomonas aeruginosa Lung Infection. Journal of Pharmaceutical Sciences, 2019, 108, 630-640.	1.6	14
226	Lipid-Based Nanoparticles for Drug Delivery Systems. , 2019, , 47-76.		103

#	ARTICLE	IF	CITATIONS
227	Safety differentiation: emerging competitive edge in drug development. <i>Drug Discovery Today</i> , 2019, 24, 285-292.	3.2	1
228	Development of Î²-â€œcarotene aerosol formulations using a modified spray dryer. <i>Journal of Food Process Engineering</i> , 2020, 43, e13233.	1.5	11
229	Engineering of Nebulized Metalâ€œPhenolic Capsules for Controlled Pulmonary Deposition. <i>Advanced Science</i> , 2020, 7, 1902650.	5.6	46
230	Inhalation of sustained release microparticles for the targeted treatment of respiratory diseases. <i>Drug Delivery and Translational Research</i> , 2020, 10, 339-353.	3.0	27
231	Development of new in vitro models of lung protease activity for investigating stability of inhaled biological therapies and drug delivery systems. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2020, 146, 64-72.	2.0	17
232	Structured micro/nano materials synthesized <i>via</i> electrospray: a review. <i>Biomaterials Science</i> , 2020, 8, 5555-5573.	2.6	53
233	Nano targeted Therapies Made of Lipids and Polymers have Promising Strategy for the Treatment of Lung Cancer. <i>Materials</i> , 2020, 13, 5397.	1.3	13
234	InÃsilico analysis of protein/peptide-based inhalers against SARS-CoV-2. <i>Future Virology</i> , 2020, 15, 557-564.	0.9	2
235	Curses or Cures: A Review of the Numerous Benefits Versus the Biosecurity Concerns of Conotoxin Research. <i>Biomedicines</i> , 2020, 8, 235.	1.4	27
236	Recent advances in the development of microparticles for pulmonary administration. <i>Drug Discovery Today</i> , 2020, 25, 1865-1872.	3.2	23
237	Pulmonary Delivery of Biological Drugs. <i>Pharmaceutics</i> , 2020, 12, 1025.	2.0	97
238	Targeted polymeric micellar systems for respiratory diseases. , 2020, , 411-439.		3
240	Model-Informed Drug Discovery and Development in Pulmonary Delivery: Biopharmaceutical Pharmacometric Modeling for Formulation Evaluation of Pulmonary Suspensions. <i>ACS Omega</i> , 2020, 5, 25733-25746.	1.6	6
241	An Overview on Spray-Drying of Protein-Loaded Polymeric Nanoparticles for Dry Powder Inhalation. <i>Pharmaceutics</i> , 2020, 12, 1032.	2.0	22
242	Nuclear factor of activated T cells as a marker of in vivo lowâ€œdose dibenzo[<i>a</i>,<i>h</i>]anthracene exposure. <i>Journal of Applied Toxicology</i> , 2020, 40, 1239-1247.	1.4	3
243	Amifostine-loaded armored dissolving microneedles for long-term prevention of ionizing radiation-induced injury. <i>Acta Biomaterialia</i> , 2020, 112, 87-100.	4.1	26
244	Pharmacokinetic Analysis of Epithelial/Endothelial Cell Barriers in Microfluidic Bilayer Devices with an Airâ€œLiquid Interface. <i>Micromachines</i> , 2020, 11, 536.	1.4	6
245	Advances in the use of cell penetrating peptides for respiratory drug delivery. <i>Expert Opinion on Drug Delivery</i> , 2020, 17, 647-664.	2.4	14

#	ARTICLE	IF	CITATIONS
246	Enhanced pulmonary systemic delivery of protein drugs via zwitterionic polymer conjugation. <i>Journal of Controlled Release</i> , 2020, 322, 170-176.	4.8	28
247	Glucose-sensitive materials for delivery of antidiabetic drugs. , 2020, , 203-228.		1
248	A Systematic Safety Evaluation of Nanoporous Mannitol Material as a Dry-Powder Inhalation Carrier System. <i>Journal of Pharmaceutical Sciences</i> , 2020, 109, 1692-1702.	1.6	9
249	Intratracheal GLP-1 receptor agonist treatment up-regulates mucin via p38 and exacerbates emphysematous phenotype in mucus hypersecretory obstructive lung diseases. <i>Biochemical and Biophysical Research Communications</i> , 2020, 524, 332-339.	1.0	7
250	Limbic encephalitis in a neuroscientist: CASPR 2 antibody-associated disease after antigen exposure. <i>Journal of Neuroimmunology</i> , 2020, 343, 577231.	1.1	1
251	Applications of Chitosan in Pulmonary Drug Delivery. , 0, , .		5
252	Ethylcellulose nanoparticles prepared from nano-emulsion templates as new folate binding haemocompatible platforms. <i>Materials Science and Engineering C</i> , 2021, 120, 111682.	3.8	5
253	Production of bromelain aerosols using spray-freeze-drying technique for pulmonary supplementation. <i>Drying Technology</i> , 2021, 39, 358-370.	1.7	6
254	Contemporary Formulation Development for Inhaled Pharmaceuticals. <i>Journal of Pharmaceutical Sciences</i> , 2021, 110, 66-86.	1.6	26
255	Nano-aerosols and Its Applications. , 2021, , 666-687.		0
256	Hot melt extrusion: An emerging manufacturing method for slow and sustained protein delivery. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2021, 13, e1712.	3.3	19
257	Aerosol Inhalation Delivery of Triazavirin in Mice: Outlooks for Advanced Therapy Against Novel Viral Infections. <i>Journal of Pharmaceutical Sciences</i> , 2021, 110, 1316-1322.	1.6	13
258	The Advantages and Challenges of Using Endolysins in a Clinical Setting. <i>Viruses</i> , 2021, 13, 680.	1.5	100
259	Novel formulations and drug delivery systems to administer biological solids. <i>Advanced Drug Delivery Reviews</i> , 2021, 172, 183-210.	6.6	25
260	Dry powder pharmaceutical biologics for inhalation therapy. <i>Advanced Drug Delivery Reviews</i> , 2021, 172, 64-79.	6.6	53
261	Association between anaphylaxis and anti-influenza drug use: An analysis of the Japanese Adverse Drug Event Report database. <i>Drug Discoveries and Therapeutics</i> , 2021, 15, 150-155.	0.6	5
262	An integrated aerosol setup for therapeutics and toxicological testing: Generation techniques and measurement instrumentation. <i>Measurement: Journal of the International Measurement Confederation</i> , 2021, 181, 109659.	2.5	4
263	Translation of pulmonary protein therapy from bench to bedside: Addressing the bioavailability challenges. <i>Journal of Drug Delivery Science and Technology</i> , 2021, 64, 102664.	1.4	6

#	ARTICLE	IF	CITATIONS
264	Dry powder inhaler formulation comparison: Study of the role of particle deposition pattern and dissolution. <i>International Journal of Pharmaceutics</i> , 2021, 607, 121025.	2.6	5
265	Current Status of Endolysin-Based Treatments against Gram-Negative Bacteria. <i>Antibiotics</i> , 2021, 10, 1143.	1.5	25
266	Inhaled RNA Therapeutics for Obstructive Airway Diseases: Recent Advances and Future Prospects. <i>Pharmaceutics</i> , 2021, 13, 177.	2.0	18
268	Noninvasive gene transfer to the lung for systemic delivery of therapeutic proteins. <i>Journal of Clinical Investigation</i> , 2002, 110, 499-504.	3.9	104
269	Inhaled Countermeasures for Respiratory Tract Viruses. , 2016, , 93-130.		1
270	Formulation Strategies and Particle Engineering Technologies for Pulmonary Delivery of Biopharmaceuticals. <i>Current Pharmaceutical Design</i> , 2015, 21, 2599-2610.	0.9	16
271	A New Era of Pulmonary Delivery of Nano-antimicrobial Therapeutics to Treat Chronic Pulmonary Infections. <i>Current Pharmaceutical Design</i> , 2016, 22, 2577-2598.	0.9	17
272	Advanced Approaches of Bioactive Peptide Molecules and Protein Drug Delivery Systems. <i>Current Pharmaceutical Design</i> , 2019, 24, 5147-5163.	0.9	9
273	Nanotechnology: Revolutionizing the Science of Drug Delivery. <i>Current Pharmaceutical Design</i> , 2019, 24, 5086-5107.	0.9	22
274	Recent Advances in Insulin Therapy for Diabetes. <i>International Journal of Diabetes and Clinical Research</i> , 2014, 1, .	0.1	3
275	Development of Otsuka dry powder inhalation system using technology of freeze-drying. <i>Drug Delivery System</i> , 2009, 24, 468-476.	0.0	5
276	Noninvasive routes of proteins and peptides drug delivery. <i>Indian Journal of Pharmaceutical Sciences</i> , 2011, 73, 367-75.	1.0	92
277	Sustained Release of Anthocyanin from Porous Poly(lactic-co-glycolide) Microspheres Developed for the Treatment of Chronic Obstructive Pulmonary Disease. <i>Journal of Pharmaceutical Investigation</i> , 2010, 40, 231-236.	2.7	3
278	Pulmonary Drug Delivery Systems for Biomacromolecules. , 2005, , 259-281.		0
279	Targeting Drugs to the Lungs – The Example of Insulin. , 2010, , 227-249.		0
280	The Delivery of Drugs – Peptides and Proteins. , 2011, , 576-593.		2
281	Nanotechnology and Nanomedicine in Diabetes. , 2012, , 3-13.		0
283	PROBLEMS AND PROSPECTS OF INHALATION APPLICATION OF PEPTIDE AND PROTEIN COMPOUNDS AS POTENTIAL MEDICAL RADIATION PROTECTIVE AGENTS. <i>Medico-Biological and Socio-Psychological Issues of Safety in Emergency Situations</i> , 2018, , 60-69.	0.2	2

#	ARTICLE	IF	CITATIONS
305	Celebrating a Century of Insulin Discovery: A Critical Appraisal of the Emerging Alternative Insulin Delivery Systems. <i>Current Drug Delivery</i> , 2023, 20, 656-668.	0.8	1
306	Protein and Peptide Drug Delivery. , 0, , .		0
307	Polymeric nanocarriers for nose-to-brain drug delivery in neurodegenerative diseases and neurodevelopmental disorders. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 1866-1886.	5.7	23
308	Progress in non-viral localized delivery of siRNA therapeutics for pulmonary diseases. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 1400-1428.	5.7	3
309	Antimicrobial peptides for tackling cystic fibrosis related bacterial infections: A review. <i>Microbiological Research</i> , 2022, 263, 127152.	2.5	7
310	Thermoresponsive polysaccharide particles: Control of dissolution and release properties. <i>Journal of Drug Delivery Science and Technology</i> , 2022, 76, 103793.	1.4	0
311	Factors Affecting Drug Exposure after Inhalation. <i>Prague Medical Report</i> , 2022, 123, 129-139.	0.4	1
312	Designing a "Ready-to-Use"™ powder formulation platform for the inhaled protein therapeutics. <i>Journal of Drug Delivery Science and Technology</i> , 2022, 76, 103820.	1.4	0
313	Bacteriophage-encoded lethal membrane disruptors: Advances in understanding and potential applications. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	4
314	Challenges and Strategies to Enhance the Systemic Absorption of Inhaled Peptides and Proteins. <i>Pharmaceutical Research</i> , 2023, 40, 1037-1055.	1.7	10
315	Nanotechnology as a tool to overcome macromolecules delivery issues. <i>Colloids and Surfaces B: Biointerfaces</i> , 2023, 222, 113043.	2.5	11
316	The Promising Therapeutic Potential of Oligonucleotides for Pulmonary Fibrotic Diseases. <i>Expert Opinion on Drug Discovery</i> , 2023, 18, 193-206.	2.5	3
317	Identification of Three Campylobacter Lysins and Enhancement of Their Anti-Escherichia coli Efficacy Using Colicin-Based Translocation and Receptor-Binding Domain Fusion. <i>Microbiology Spectrum</i> , 2023, 11, .	1.2	0
318	Recent advances in respiratory immunization: A focus on COVID-19 vaccines. <i>Journal of Controlled Release</i> , 2023, 355, 655-674.	4.8	7
319	Shaping the future from the small scale: dry powder inhalation of CRISPR-Cas9 lipid nanoparticles for the treatment of lung diseases. <i>Expert Opinion on Drug Delivery</i> , 2023, 20, 471-487.	2.4	4
320	Advanced Formulation Approaches for Proteins. <i>Handbook of Experimental Pharmacology</i> , 2023, , .	0.9	0
322	Nano-mediated strategy for targeting and treatment of non-small cell lung cancer (NSCLC). <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2023, 396, 2769-2792.	1.4	2
330	Pulmonary Delivery of Antibody for the Treatment of Respiratory Diseases. <i>AAPS Introductions in the Pharmaceutical Sciences</i> , 2023, , 21-51.	0.1	0

#	ARTICLE	IF	CITATIONS
331	Design Strategies of Dry Powders for Pulmonary Delivery of Pharmaceutical Peptides. AAPS Introductions in the Pharmaceutical Sciences, 2023, , 1-20.	0.1	0
332	Pulmonary Delivery of Nucleic Acids. AAPS Introductions in the Pharmaceutical Sciences, 2023, , 93-122.	0.1	0